Response to Letter. “Romosozumab and cardiovascular safety- should we learn lessons from Pioglitazone?.”

Saved in:
Bibliographic Details
Published in:Osteoporosis international 2022-06, Vol.33 (6), p.1401-1402
Main Authors: Tominaga, Ayako, Wada, Keiji, Okazaki, Ken, Nishi, Hideharu, Terayama, Yasushi, Kato, Yoshiharu
Format: Article
Language:English
Subjects:
Endocrinology
Letter to the Editor
Medicine
Medicine & Public Health
Orthopedics
Pioglitazone
Rheumatology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0937-941X
1433-2965
DOI:10.1007/s00198-022-06300-6